Advances in resistant hypertension - Wikidata - awgldk - TriplyDB

Advances in resistant hypertension

Advances in resistant hypertension

http://www.wikidata.org/entity/Q58804818

about

Advances in resistant hypertension

http://www.wikidata.org/entity/Q58804818

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Advances in resistant hypertension

@en

Advances in resistant hypertension

@nl

type

label

Advances in resistant hypertension

@en

Advances in resistant hypertension

@nl

prefLabel

Advances in resistant hypertension

@en

Advances in resistant hypertension

@nl

P1433

Q58804818-43B0F618-5611-4551-8564-789DC3578FC7

P1476

Q58804818-A6065EA8-5B78-4EED-9F05-E5E0EACBA5FF

P2093

Q58804818-419B0594-8A6D-4D61-98A9-8C7EED025F30

P2860

Q58804818-0B226AB3-2B9A-44D1-A316-ACFCF1309D2B

Q58804818-25C2F7FF-5F8A-42AD-AD84-3676A0C2150F

Q58804818-2D4E6B96-ACA4-463E-BDE4-695AE5E87767

Q58804818-653A25CC-CA00-4EF4-8ADC-B3F5F2CE3CED

Q58804818-765AE8EC-4B07-43B4-956B-9B5C84ECF1C9

Q58804818-88188BC7-E69A-4491-A6B4-698769304CCE

Q58804818-B3F86737-0358-4065-85C7-B39E2C9CA3CF

Q58804818-D4EF4DD2-D3E6-4C12-82AC-56E44C360BBB

Q58804818-DECFBA9E-43BC-40D2-9E9A-C6B7996D8788

P304

Q58804818-C38E20E7-6C5E-495F-9ADB-08978A64C7F5

P31

Q58804818-6eea3a62-c53d-4ef3-b208-5ffc74534f49

Q58804818-FE933E26-50F8-4E3B-80CB-9BDF86E3F4E3

P356

Q58804818-84F9C142-6D93-45EE-9D9F-5320A32C0A61

P407

Q58804818-74331EE0-E1BE-439D-9273-418ECBB00A2B

P433

Q58804818-BA62866D-B39E-4A90-8CAD-7A96DE2A4535

P478

Q58804818-DFA49729-651F-424D-916C-CA626A788EBF

P577

Q58804818-64BA043A-1B0F-43EA-930E-A03A31456BBC

P698

Q58804818-2C49A774-818D-41D8-BEB4-6FFA9CC51655

P932

Q58804818-8DF62482-AD95-4DBC-97C5-9EDB9CC383BD

P356

P1433

Annals of translational medicine

P1476

Advances in resistant hypertension

@en

P2093

David A Calhoun

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.

Clinical characteristics of patients with resistant hypertension: the RESIST-POL study.

Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clini

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

P304

294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2018.07.21

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30211182

http://www.w3.org/2001/XMLSchema#string

P932

6123198

http://www.w3.org/2001/XMLSchema#string